Financial Performance - The company's revenue decreased by 21.9% from RMB 8,983 million in 2024 Q1 to RMB 7,015 million in 2025 Q1[19] - Gross profit decreased by 27.6% from RMB 6,495 million in 2024 Q1 to RMB 4,705 million in 2025 Q1[19] - Gross profit margin decreased by 5.2 percentage points from 72.3% in 2024 Q1 to 67.1% in 2025 Q1[19] - Reported profit attributable to shareholders of the company decreased by 8.4% from RMB 1,613 million in 2024 Q1 to RMB 1,478 million in 2025 Q1[19] - Underlying profit attributable to shareholders of the company decreased by 18.2% from RMB 1,724 million in 24Q1 to RMB 1,411 million in 25Q1[19] - Finished drugs revenue decreased by 27.3% from RMB 7,561 million in 24Q1 to RMB 5,500 million in 25Q1[21] - Bulk vitamin C revenue increased by 25.0% from RMB 486 million in 24Q1 to RMB 608 million in 25Q1[21] - Bulk antibiotics revenue increased by 3.3% from RMB 449 million in 24Q1 to RMB 464 million in 25Q1[21] R&D and Pipeline - The company has 8 R&D platforms and over 200 innovative drugs and new formulations under development[4] - R&D expenses increased by 11.4% from RMB 1,169 million in 2024 Q1 to RMB 1,302 million in 2025 Q1[19] - The company has 5 R&D centers located in China and the U S[99] Business Development - Up to May 2025, a total of HK$300 million has been repurchased[8]
石药集团(01093) - 2025 Q1 - 电话会议演示